SEC Company Response from Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Jul 15, 2019

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: July 15, 2019 · CIK: 0001430306 · Accession: 0001387131-19-005031

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-232195

Date

July 15, 2019

Author

TONIX PHARMACEUTICALS HOLDINGS

Form

CORRESP

Company

Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)

Letter

Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue, Suite 1608

New York, New York 10022

July 15, 2019

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 (File No. 333-232195)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on July 15, 2019, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
TONIX PHARMACEUTICALS HOLDINGS
CORP.

Show Raw Text

CORRESP
1
filename1.htm

Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue, Suite 1608

New York, New York 10022

July
15, 2019

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

 Re: Tonix
                                         Pharmaceuticals Holding Corp.
 Registration Statement on Form S-1 (File No. 333-232195)

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”)
hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared
effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time,
on July 15, 2019, or as soon as practicable thereafter.

Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement
or with any questions.

    Very truly yours,

    TONIX PHARMACEUTICALS HOLDINGS
CORP.

    By:
    /s/
    Bradley Saenger

    Name:

    Bradley Saenger

    Title:

    Chief Financial Officer

SecProbe.io